Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNV-2
- Development stage
- Unknown
- Lead developer
- Calidi Biotherapeutics
- Modality
- Stem Cell Therapies → Cell Therapies, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral
01
Overview
**NNV-2 (NeuroNova, NSC-CRAd-S-pk7)** is an allogeneic, off-the-shelf oncolytic virotherapy platform developed by Calidi Biotherapeutics. It consists of immortalized tumor-tropic neural stem cells (NSCs) engineered to deliver an oncolytic adenovirus (CRAd-S-pk7) selectively to tumor sites, acting as a "Trojan horse" to shield the virus from immune inactivation, enable efficient tumor infiltration, and induce viral replication, tumor cell lysis, and a secondary anti-tumor immune response. Primarily indicated for high-grade gliomas, it is administered via injection into the tumor resection cavity walls post-surgery. Calidi holds exclusive worldwide licensing rights to the underlying patents, with prior Phase 1 data in newly diagnosed glioma showing good tolerability and promising efficacy when combined with radiation and temozolomide.[1][4][5]
- Other names
- NeuroNova (NNV2)
Beyond the preview
Go deeper on NNV-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNV-2.